ArticleFrontiers in pharmacology2023

The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients.

Jing Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.